ATAIBECKLEY Aktie

 

Die wissenschaftliche Evidenz für den Einsatz von Psilocybin zur Behandlung therapieresistenter Depressionen nimmt weiter zu. Zuletzt sorgten neue klinische Studien sowie die milliardenschwere Übernahme von AtaiBeckley durch Eli Lilly für große Aufmerksamkeit in der medizinischen Fachwelt. Parallel dazu zeigen Forschungsergebnisse des australischen Branchenpioniers Emyria Limited, dass psychedelisch unterstützte Therapien bei posttraumatischen Belastungsstörungen (PTBS) bereits heute deutliche und langfristige Verbesserungen für The post Psychedelika vor dem Milliarden-Durchbruch: Warum Eli Lillys Deal den Beginn eines neuen Therapiemarktes markieren könnte appeared first on IRW-Press....

Cathie Wood is loading up on shares of a biotech that could be one of the first entrants to the psychedelics market....

Lilly's purchase of AtaiBeckley is yet another strategic move in its bid to diversify its pipeline....

Eli Lilly's acquisition of psychedelic drug maker AtaiBeckley extends Big Pharma's embrace of a stigmatized class of medications for treating mental health....

BASEL (dpa-AFX) - This week, the healthcare sector saw multiple U.S FDA and European Commission approvals, strategic licensing and M&A activity, as well as pivotal clinical trial readouts and regu......

LLY agrees to acquire AtaiBeckley for $2.8B upfront to expand its neuroscience pipeline with psychedelic therapies for mental health disorders....

Als boersengefluester.de Mitte Juni 2021 die Aktien von AtaiBeckley - damals noch firmierend als Atai - in das Coverage-Universum aufgenommen hatte, hätte die Story exotischer kaum sein können. Imm......

Biotech Growth Trust PLC - London-based investment trust - Eli Lilly & Co intends to acquire portfolio company AtaiBeckley...

Issued on behalf of Helus Pharma™ Eli Lilly's agreement to acquire AtaiBeckley for up to $3.8 billion hands psychedelic medicine its first large-cap validation, and it lands on a late-stage cohort already carrying pivotal data into the back half of 2026, among them Helus Pharma™ (NASDAQ:......

Der CEO von All for One sagte mir noch im Mai im AKTIONÄR TV, er sei „sehr glücklich“ mit seinen Aktien – nun die Kursverdopplung. Auch das Spezial-Pharma-Start-up AtaiBeckley feiert ein Happy End – mit 400 Prozent Kursgewinn....

17 July 2026   THE BIOTECH GROWTH TRUST PLC (“BIOG” or the "Company")   Eli Lilly to acquire BIOG portfolio company, AtaiBeckley Inc.   The Company notes the announcement on Thursday, 16 July 2026 that Eli Lilly and Company has announced its intention to acquire BIOG portfolio company, AtaiBeckley Inc. (“AtaiBeckley”) for approximately $2.8 billion, or $6.75 a share, in cash representing a 26% premium to AtaiBeckley's closing price on Wednesday, 15 July 2026.  The offer also includes an additional approximately $1 billion in contingent value right payments which are...

Today's top gainers in the biotech space include CareDx, which rallied after Medicare finalized its Local Coverage Determination process for molecular testing of solid organ allograft rejection; AtaiBeckley, after agreeing to be acquired by Eli Lilly; and Abbott, after reporting second-quarter results and providing an upbeat outlook, among others....

The psychedelic drugmaker is being acquired....

Today, July 16, 2026, the clinical-stage psychedelics developer jumped 33% after Lilly announced a cash deal plus milestone payments....

NEW YORK, July 16, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The......

CNBC pharma reporter Angelica Peebles broke down the biggest psychedelics deal in Big Pharma history on July 16, 2026. She framed Eli Lilly's (NYSE: LLY) acquisition of Atai Beckley as a bet on rewiring the brain rather than merely dampening symptoms. “Lilly says that it is acquiring psychedelic drug developer Atai Beckley, and Lilly will pay $6.75 ... Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug...

Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...

MILWAUKEE, July 16, 2026 /PRNewswire/ -- Ademi LLP is investigating AtaiBeckley (Nasdaq: ATAI) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Eli Lilly. Click here to learn how to join our investigation and obtain additional......

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

LOWELL (dpa-AFX) - At 8:40 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening bell......